United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories limited - ibandronate sodium (unii: j12u072ql0) (ibandronic acid - unii:umd7g2653w) - ibandronic acid 150 mg - ibandronate sodium tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women. ibandronate sodium tablets increases bone mineral density (bmd) and reduces the incidence of vertebral fractures. the optimal duration of use has not been determined. the safety and effectiveness of ibandronate sodium tablets for the treatment of osteoporosis are based on clinical data of three years duration. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. ibandronate sodium tablets are contraindicated in patients with the following conditions: - abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia (see warnings and precautions [5.1] )   - inability to stand or sit upright for at least 60

United States - English - NLM (National Library of Medicine)

virtus pharmaceuticals - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - losartan potassium 25 mg - losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and myocardial infarction. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - maraviroc - tablet, film coated - 300mg - maraviroc 300mg

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - raltegravir potassium 434.4mg eqv free phenol - tablet, film coated - 400 mg - raltegravir potassium 434.4mg eqv free phenol 400 mg

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - raltegravir potassium 108.6 mg eqv raltegravir - tablet, chewable - 100 mg - raltegravir potassium 108.6 mg eqv raltegravir 100 mg

Singapore - English - HSA (Health Sciences Authority)

roche singapore pte. ltd. - ribavirin - tablet, film coated - 200 mg - ribavirin 200 mg

Singapore - English - HSA (Health Sciences Authority)

viatris private limited - sildenafil citrate 140.450mg eqv sildenafil - tablet, film coated - 100 mg - sildenafil citrate 140.450mg eqv sildenafil 100mg

Singapore - English - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - nevirapine - tablet - 200 mg - nevirapine 200 mg

Singapore - English - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - nevirapine anhydrous - tablet, extended release - 400 mg - nevirapine anhydrous 400 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - belimumab 400mg - powder for injection - 400 mg - active: belimumab 400mg excipient: citric acid monohydrate polysorbate 80 sodium citrate dihydrate sucrose - benlysta is indicated as add-on therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus (sle) with a high degree of disease activity (e.g. ana titre > 1:80 and/or anti-dsdna titre > 30 iu/ml) despite standard therapy. the safety & efficacy of benlysta have not been evaluated in patients with severe active lupus nephritis or severe active cns lupus.